Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K. Tzelepis K, et al. Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079. Cell Rep. 2016. PMID: 27760321 Free PMC article.
Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream treatments have not changed for decades. To identify additional therapeutic targets in AML, we optimize a genome-wide clustered
Acute myeloid leukemia (AML) is an aggressive cancer with a poor prognosis, for which mainstream treatments have
Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML.
Basheer FT, Vassiliou GS. Basheer FT, et al. Curr Opin Genet Dev. 2019 Feb;54:83-87. doi: 10.1016/j.gde.2019.04.004. Epub 2019 May 4. Curr Opin Genet Dev. 2019. PMID: 31063922 Review.
Recently the use of CRISPR-Cas9 systems for genome editing and their potential application in genome-wide screening has opened a new frontier for unbiased discovery of therapeutic vulnerabilities in cancer and AML was the first disease in which …
Recently the use of CRISPR-Cas9 systems for genome editing and their potential application in genome-wide screening has opened …
Feedback